Ensuring center quality, proper patient selection and fair access to chimeric antigen receptor T-cell therapy: position statement of the Austrian CAR-T Cell Network

Tools

Preview	PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader 732kB
	MS Word (Supplementary Material) 59kB

Item Type:	Article
Title:	Ensuring center quality, proper patient selection and fair access to chimeric antigen receptor T-cell therapy: position statement of the Austrian CAR-T Cell Network
Creators Name:	Greinix, H.T., Attarbaschi, A., Girschikofsky, M., Greil, R., Holter, W., Neumeister, P., Peters, C., Petzer, A., Rudzki, J., Schlenke, P., Schmitt, C.A., Schwinger, W., Wolf, D., Worel, N. and Jaeger, U.
Abstract:	Chimeric antigen receptor T cells (CAR-T cells) are a novel form of cellular immunotherapy for patients with hematologic and oncologic malignancies. Known side effects of these approved cellular immunotherapies are cytokine release syndrome, immune-cell associated neurotoxicity syndrome, cytopenias, infections and long-lasting B cell aplasia. Safe administration of CAR-T cell therapy requires thorough patient selection and patient care in qualified CAR-T cell centers.
Keywords:	CAR-T Cells, Position Statement, Network, Patient Selection Criteria, Infrastructure Requirements
Source:	memo: Magazine of European Medical Oncology
ISSN:	1865-5041
Publisher:	Springer
Volume:	13
Number:	1
Page Range:	27-31
Date:	March 2020
Official Publication:	https://doi.org/10.1007/s12254-020-00582-4

Repository Staff Only: item control page

Download Statistics

Downloads

Downloads per month over past year